Back to Startup Insights
Fusix Biotech logo

Fusix Biotech

Fusix Biotech is developing next-generation cancer immunotherapies.

Headquarters

Berlin, Germany

Year Founded

2022

Founders

Dr. Max Müller

Country

Germany

Financial Information

Funding Stage

Seed

Recent Funding

$580k

Funding By

BioNTech

Core Technology

Cancer immunotherapy

Product Type

Drug

Pipeline Stage (Very Important)

Preclinical

Regulatory Status

  • IND Filed: No
  • FDA/EMA Status: N/A
  • Clinical Trial Registration: N/A
  • Patents / IP Status: Filed

Partnerships

Pharma Collaborations

BioNTech

Academic / Hospital Tie-ups

Charité Berlin

CRO/CDMO Partnerships

None

Market & Differentiation

Next-gen immunotherapy

Startup Insights - Discover Healthcare Innovation | Pharmalenz